510(k) · Cleared
ClearedHemochron JR. Signature +
Data to Oct 25, 2026 (FDA decisions) Oct 12, 2026 (recalls) Sep 30, 2026 (MAUDE) refreshed weekly
International Technidyne Corp. · JPA System, Multipurpose For In Vitro Coagulation Studies
Cleared on Mar 28, 2002 as substantially equivalent to K974799 (International Technidyne Corp., 1998) after a 16-day review. Its family tree reaches back 2 generations to 1993. 3 later devices descend from it.
- Decided
- Mar 28, 2002
- Review
- 16 days
- Class
- Class II
- Product code
- JPA
- Recalls
- None
- Predicates
- 1
Its longest line of descent runs back 2 generations to K923761 (1993). 3 ancestors in all. 3 later devices descend from it, 1 citing it directly.
- Root · 2 generations backK923761 Itc Microsample Coagulation Analyzer SystemInternational Technidyne Corp. · 1993
- 1 generation backK974799 Hemochron JR Generation II, Hemochron JR SignatureInternational Technidyne Corp. · 1998 · Recalled
- This deviceK020798 Hemochron JR. Signature +International Technidyne Corp. · 2002
- Descendant · cites it directly · 2 of its ownK050016 Hemochron Signature EliteInternational Technidyne Corp. · 2005
- Descendant · 2 generations on · 1 of its ownK193041 Hemochron Signature EliteAccriva Diagnostics, Inc. · 2019
- Descendant · 3 generations on · 0 of its ownK202101 GEM Hemochron 100 System, GEM Hemochron 100 Activated Clotting Time…Accriva Diagnostics, Inc. · 2021 · Recalled
Most influential descendants
Showing 3 of 3 · See all- K050016Hemochron Signature EliteInternational Technidyne Corp. · 2005 · cites it directly2descendants
- K193041Hemochron Signature EliteAccriva Diagnostics, Inc. · 2019 · 2 generations on1descendant
- K202101GEM Hemochron 100 System, GEM Hemochron 100 Activated Clotting Time Plus Test (ACT+)…Accriva Diagnostics, Inc. · 2021 · 3 generations on0descendants
View FIG. 1 as a table
Line of descent and top descendants
| Generation | Number | Device | Applicant | Decided | Recalls |
|---|---|---|---|---|---|
| −2 | K923761 | Itc Microsample Coagulation Analyzer System | International Technidyne Corp. | 1993 | — |
| −1 | K974799 | Hemochron JR Generation II, Hemochron JR Signature | International Technidyne Corp. | 1998 | 2 |
| 0 (this device) | K020798 | Hemochron JR. Signature + | International Technidyne Corp. | 2002 | — |
| +1 | K050016 | Hemochron Signature Elite | International Technidyne Corp. | 2005 | — |
| +2 | K193041 | Hemochron Signature Elite | Accriva Diagnostics, Inc. | 2019 | — |
| +3 | K202101 | GEM Hemochron 100 System, GEM Hemochron 100 Activated Clotting Time Plus Test… | Accriva Diagnostics, Inc. | 2021 | 1 |
Other ancestors by year cleared
| Year cleared | Devices | With a Class I recall |
|---|---|---|
| 1994 | 1 | 0 |
Descendants by year cleared
| Year cleared | Devices | With a Class I recall |
|---|---|---|
| 2005 | 1 | 0 |
| 2019 | 1 | 0 |
| 2021 | 1 | 0 |
Sources: FDA 510(k) database (decision fields), the FDA summary (predicates and indications), FDA recall and enforcement reports, and MAUDE; processed by 510(k) Report. Verify on FDA.gov · Methodology and accuracy.
Planning a device in JPA? A 510(k) Report weighs predicate choices, recall history and review times for a new device like this one.
Top candidate predicates for a new JPA device
- #1 K243858 TEG 6s Hemostasis System Citrated: K, KH, RT…score 12.0 · 2 generations · no Class I recall
- #2 Held for the reportin the report
- #3 Held for the reportin the report
What was it cleared against? (1)
Devices the submitter claimed this one is substantially equivalent to (*), and reference devices cited for a specific test or feature (†), as written in the FDA summary.
| Type | Number | Device | Decided |
|---|---|---|---|
| * | K974799 | Hemochron JR Generation II, Hemochron JR SignatureSummary page 1…ystem Product Name: HEMOCHRON® Jr. Signature + Predicate Device The Signature+ is substantially equivalent to the previously cleared Hemochron Jr. Signature instrument K974799. Device Description and Technological Characteristics The Hemochron Jr. Signature + instrument is an upgrade to the current Hem… | 1998 |
What descends from it? (3)
1 later device cites it directly; ranked here by how many devices descend from each in turn.
| Number | Device | Decided | Descendants |
|---|---|---|---|
| K050016 | Hemochron Signature Elite | 2005 | 2 |
Has anything in its family been recalled? (0 Class I)
No FDA recall names this device.
No ancestor or descendant has a Class I recall.
What does this lineage say?
- The line of descent spans 9 years and passes through 1 company; a new generation was cleared every 5.5 years on median.
- 2 of the 3 ancestors have a recall of any class.
- Of its descendants, K050016 (International Technidyne Corp., 2005) has gone furthest, with 2 descendants of its own.
How does its category compare?
All JPA devicesJPA System, Multipurpose For In Vitro Coagulation Studies: FDA decisions, review times, recalls and adverse event reports over 20 years.
FDA decisions per year · JPA
3in 2025
2026 to Oct 25, outlined.
Median 510(k) review, days · JPA
30in 2025
Receipt to decision; years with fewer than 3 clearances left blank.
Recalls per year · JPA
1in 2020
Class I (0 since 2007) Class II/III not classified
Adverse event reports per year · JPA
11in 2025
MAUDE reports naming product code JPA, not matched to any one device; reports are not rates.
View these four charts as a table
| Year | Decisions | Median 510(k) review, days | Recalls (Class I) | MAUDE reports |
|---|---|---|---|---|
| 2007 | 1 | — | 1 | 1,744 |
| 2008 | 2 | — | 0 | 918 |
| 2009 | 6 | 91 | 0 | 1,363 |
| 2010 | 1 | — | 6 | 727 |
| 2011 | 1 | — | 4 | 161 |
| 2012 | 0 | — | 1 | 52 |
| 2013 | 1 | — | 0 | 43 |
| 2014 | 0 | — | 0 | 48 |
| 2015 | 2 | — | 0 | 45 |
| 2016 | 6 | 114 | 3 | 6 |
| 2017 | 4 | 117 | 0 | 15 |
| 2018 | 1 | — | 0 | 39 |
| 2019 | 3 | 175 | 0 | 27 |
| 2020 | 0 | — | 1 | 18 |
| 2021 | 1 | — | 0 | 7 |
| 2022 | 1 | — | 0 | 9 |
| 2023 | 3 | 506 | 0 | 11 |
| 2024 | 1 | — | 0 | 8 |
| 2025 | 3 | 30 | 0 | 11 |
| 2026 | 1 | — | 1 | — |
What is it indicated for?
The HEMOCHRON® Signature+ is a portable, battery-operated point of care microcoagulation instrument designed to perform whole blood coagulation tests using fresh or citrated whole blood. The system is intended for use in many clinical settings requiring point-of-care testing. Whole blood test results are displayed as clotting times (in seconds). The Signature+ also displays correlated celite equivalent ACT values, APTT and PT plasma equivalent values, and the PT INR value.
For In Vitro Diagnostic Use Only
Indications for use read by OCR from a scanned FDA summary, so letters may be misread. Check the PDF before quoting it.
https://510kreport.com/device/K020798 · printed Nov 6, 2026
Cite this page
510(k) Report. “K020798: Hemochron JR. Signature +.” Lineage record from FDA 510(k) data and the FDA summary. Updated Nov 3, 2026. Accessed Nov 6, 2026. https://510kreport.com/device/K020798
Report an extraction error
Are you the manufacturer?
Record history
- FDA decision record loaded May 2, 2026
- Summary read Oct 13, 2026 (extraction version 9eaa42aa01ed)
- Lineage and recalls computed Nov 3, 2026
- Page last updated Nov 3, 2026